MonarchE: A randomized, open-label, phase 3 study of abemaciclib combined with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone in patients with high risk, node positive, early stage, HR+, HER2-breast cancer

被引：0

作者：

Rastogi, Priya

Toi, Masakazu

Harbeck, Nadia

Bourayou, Nawel

Frenzel, Martin

Johnston, Stephen

机构：

[1] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA

[2] Kyoto Univ, Grad Sch Med, Kyoto, Japan

[3] Univ Munich LMU, Breast Ctr, Munich, Germany

[4] Eli Lilly & Co, Paris, France

[5] Eli Lilly & Co, Indianapolis, IN 46285 USA

[6] Royal Marsden NHS Fdn Trust, London, England

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

OT3-05-05

引用

页数：1